Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
AI Time Series Model Boosts EEG-Based Seizure Prediction by 44%
UC Santa Cruz engineers' 'future-guided' deep learning improves seizure prediction accuracy using EEG data.
•EurekAlert
NTU Singapore to Launch Master's in AI in Medicine for Clinicians and Technologists
NTU Singapore will launch a new MSc in Artificial Intelligence in Medicine to train clinicians and technologists in clinical AI applications from 2026.
•EurekAlert
AI Accurately Predicts Lymph Node Extension in HPV-related Throat Cancer via CT
An AI pipeline automates lymph node segmentation and extranodal extension prediction from CT in HPV-positive oropharyngeal cancer, correlating with patient outcomes.